HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy
Tyrosine kinase inhibitors (TKIs) have emerged as a potential treatment strategy for glioblastoma multiforme (GBM). However, their efficacy is limited by various drug resistance mechanisms. To devise more effective treatments for GBM, genetic characteristics must be considered in addition to pre-exi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Animal Cells and Systems |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19768354.2024.2347538 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849739528009416704 |
|---|---|
| author | Ju Young Lee Jongkeun Park Dongwan Hong |
| author_facet | Ju Young Lee Jongkeun Park Dongwan Hong |
| author_sort | Ju Young Lee |
| collection | DOAJ |
| description | Tyrosine kinase inhibitors (TKIs) have emerged as a potential treatment strategy for glioblastoma multiforme (GBM). However, their efficacy is limited by various drug resistance mechanisms. To devise more effective treatments for GBM, genetic characteristics must be considered in addition to pre-existing treatments. We performed an integrative analysis with heterogeneous GBM datasets of genomic, transcriptomic, and proteomic data from DepMap, TCGA and CPTAC. We found that poor prognosis was induced by co-upregulation of heat shock protein family A member 5 (HSPA5) and fibroblast growth factor receptor 1 (FGFR1). Co-up regulation of these two genes could regulate the PI3K/AKT pathway. GBM cell lines with co-upregulation of these two genes showed higher drug sensitivity to PI3K inhibitors. In the mesenchymal subtype, the co-upregulation of FGFR1 and HSPA5 resulted in the most malignant subtype of GBM. Furthermore, we found this newly discovered subtype was correlated with homologous recombination deficiency (HRD) In conclusion, we discovered novel druggable candidates within the group exhibiting co-upregulation of these two genes in GBM, suggest potential strategies for combination therapy. |
| format | Article |
| id | doaj-art-26d79f4d4ab7426ab2628d192cc2c124 |
| institution | DOAJ |
| issn | 1976-8354 2151-2485 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Animal Cells and Systems |
| spelling | doaj-art-26d79f4d4ab7426ab2628d192cc2c1242025-08-20T03:06:14ZengTaylor & Francis GroupAnimal Cells and Systems1976-83542151-24852024-12-0128121622710.1080/19768354.2024.2347538HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacyJu Young Lee0Jongkeun Park1Dongwan Hong2Department of Biomedicine and Health, The Catholic University of Korea, Seoul, Republic of KoreaDepartment of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDepartment of Biomedicine and Health, The Catholic University of Korea, Seoul, Republic of KoreaTyrosine kinase inhibitors (TKIs) have emerged as a potential treatment strategy for glioblastoma multiforme (GBM). However, their efficacy is limited by various drug resistance mechanisms. To devise more effective treatments for GBM, genetic characteristics must be considered in addition to pre-existing treatments. We performed an integrative analysis with heterogeneous GBM datasets of genomic, transcriptomic, and proteomic data from DepMap, TCGA and CPTAC. We found that poor prognosis was induced by co-upregulation of heat shock protein family A member 5 (HSPA5) and fibroblast growth factor receptor 1 (FGFR1). Co-up regulation of these two genes could regulate the PI3K/AKT pathway. GBM cell lines with co-upregulation of these two genes showed higher drug sensitivity to PI3K inhibitors. In the mesenchymal subtype, the co-upregulation of FGFR1 and HSPA5 resulted in the most malignant subtype of GBM. Furthermore, we found this newly discovered subtype was correlated with homologous recombination deficiency (HRD) In conclusion, we discovered novel druggable candidates within the group exhibiting co-upregulation of these two genes in GBM, suggest potential strategies for combination therapy.https://www.tandfonline.com/doi/10.1080/19768354.2024.2347538Glioblastoma multiformeheat shock protein family A member 5fibroblast growth factor receptor 1mesenchymal subtypecombination treatment |
| spellingShingle | Ju Young Lee Jongkeun Park Dongwan Hong HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy Animal Cells and Systems Glioblastoma multiforme heat shock protein family A member 5 fibroblast growth factor receptor 1 mesenchymal subtype combination treatment |
| title | HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy |
| title_full | HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy |
| title_fullStr | HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy |
| title_full_unstemmed | HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy |
| title_short | HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy |
| title_sort | hspa5 and fgfr1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy |
| topic | Glioblastoma multiforme heat shock protein family A member 5 fibroblast growth factor receptor 1 mesenchymal subtype combination treatment |
| url | https://www.tandfonline.com/doi/10.1080/19768354.2024.2347538 |
| work_keys_str_mv | AT juyounglee hspa5andfgfr1genesinthemesenchymalsubtypeofglioblastomacanimproveatreatmentefficacy AT jongkeunpark hspa5andfgfr1genesinthemesenchymalsubtypeofglioblastomacanimproveatreatmentefficacy AT dongwanhong hspa5andfgfr1genesinthemesenchymalsubtypeofglioblastomacanimproveatreatmentefficacy |